Any feedback?
Literature summary extracted from
- Survival of rats with experimental chronic heart failure depending on pharmacodynamic and pharmacokinetic parameters of angiotensin-converting enzyme inhibitors and beta-adrenoceptor blockers (2006), Bull. Exp. Biol. Med., 141, 40-43.
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 3.4.15.1 | medicine | combination therapy with an angiotensin-converting enzyme inhibitor and beta-adrenoceptor blocker without intrinsic sympathomimetic activity should be used in the therapy of chronic heart failure | Rattus norvegicus |
Inhibitors
| EC Number | Inhibitors | Comment | Organism | Structure |
|---|---|---|---|---|
| 3.4.15.1 | captopril | lipophilic ACE inhibitors quinapril, enalapril, and captopril increase the survival and lifetime of rats with experimental chronic heart failure | Rattus norvegicus |  |
| 3.4.15.1 | enalapril | lipophilic ACE inhibitors quinapril, enalapril, and captopril increase the survival and lifetime of rats with experimental chronic heart failure | Rattus norvegicus | |
| 3.4.15.1 | quinapril | lipophilic ACE inhibitors quinapril, enalapril, and captopril increase the survival and lifetime of rats with experimental chronic heart failure | Rattus norvegicus | |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.15.1 | Rattus norvegicus | - |
with experimental chronic heart failure | - |
Source Tissue
| EC Number | Source Tissue | Comment | Organism | Textmining |
|---|
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
